Cargando…

Duloxetine use in chronic painful conditions – individual patient data responder analysis

BACKGROUND: Duloxetine has been studied in four distinct chronic pain conditions – osteoarthritis (OA), fibromyalgia, chronic low back pain (CLBP) and diabetic peripheral neuropathic pain (DPNP). These trials have involved large numbers of patients with at least moderate pain, and have used similar...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, RA, Cai, N, Skljarevski, V, Tölle, T R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302330/
https://www.ncbi.nlm.nih.gov/pubmed/23733529
http://dx.doi.org/10.1002/j.1532-2149.2013.00341.x
_version_ 1782353778410782720
author Moore, RA
Cai, N
Skljarevski, V
Tölle, T R
author_facet Moore, RA
Cai, N
Skljarevski, V
Tölle, T R
author_sort Moore, RA
collection PubMed
description BACKGROUND: Duloxetine has been studied in four distinct chronic pain conditions – osteoarthritis (OA), fibromyalgia, chronic low back pain (CLBP) and diabetic peripheral neuropathic pain (DPNP). These trials have involved large numbers of patients with at least moderate pain, and have used similar methods for recording pain intensity, over about 12 weeks. METHODS: Data from the trials were pooled according to painful condition, and reanalysed at the level of the individual patient and using increasing levels of pain intensity reduction (<15%, 15–29%, 30–49%, ≥50%), with different imputation methods on withdrawal. RESULTS: The proportion of patients recording at least 50% pain intensity reduction plateaued after 2–6 weeks in fibromyalgia, and 8–12 weeks in other conditions. The duloxetine-specific benefit [number needed to treat (NNT) for at least 50% pain intensity reduction] was fairly constant after about 2 weeks for DPNP and fibromyalgia and after about 4 or 5 weeks for OA and CLBP. In all conditions, responses were bimodal, with patients generally experiencing either very good or very poor pain relief. Last-observation-carried-forward imputation produced numerically and occasionally statistically better (lower) NNTs than use of baseline-observation-carried-forward (true response). CONCLUSIONS: Baseline-observation-carried-forward (true response), which combines the success of high levels of pain relief with the failure to experience pain relief on withdrawal of the drug is conservative and probably reflective of clinical practice experience. The distribution of effect was not normal; few patients had the average response and averages are not an appropriate descriptor for these data. WHAT'S ALREADY KNOWN ABOUT THIS TOPIC? Last-observation-carried-forward (LOCF) imputation overestimates efficacy when adverse event withdrawals are high. Previous analyses of duloxetine in four chronic pain conditions reported mainly average pain changes using LOCF imputation. WHAT DOES THIS STUDY ADD? Responses were bimodal: patients generally experienced very good or very poor pain relief. Last-observation-carried-forward results were numerically lower (better) than true responder. Duloxetine was an effective analgesic in all four chronic pain conditions using highest level of evidence.
format Online
Article
Text
id pubmed-4302330
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-43023302015-01-29 Duloxetine use in chronic painful conditions – individual patient data responder analysis Moore, RA Cai, N Skljarevski, V Tölle, T R Eur J Pain Experimental & Clinical Pharmacology BACKGROUND: Duloxetine has been studied in four distinct chronic pain conditions – osteoarthritis (OA), fibromyalgia, chronic low back pain (CLBP) and diabetic peripheral neuropathic pain (DPNP). These trials have involved large numbers of patients with at least moderate pain, and have used similar methods for recording pain intensity, over about 12 weeks. METHODS: Data from the trials were pooled according to painful condition, and reanalysed at the level of the individual patient and using increasing levels of pain intensity reduction (<15%, 15–29%, 30–49%, ≥50%), with different imputation methods on withdrawal. RESULTS: The proportion of patients recording at least 50% pain intensity reduction plateaued after 2–6 weeks in fibromyalgia, and 8–12 weeks in other conditions. The duloxetine-specific benefit [number needed to treat (NNT) for at least 50% pain intensity reduction] was fairly constant after about 2 weeks for DPNP and fibromyalgia and after about 4 or 5 weeks for OA and CLBP. In all conditions, responses were bimodal, with patients generally experiencing either very good or very poor pain relief. Last-observation-carried-forward imputation produced numerically and occasionally statistically better (lower) NNTs than use of baseline-observation-carried-forward (true response). CONCLUSIONS: Baseline-observation-carried-forward (true response), which combines the success of high levels of pain relief with the failure to experience pain relief on withdrawal of the drug is conservative and probably reflective of clinical practice experience. The distribution of effect was not normal; few patients had the average response and averages are not an appropriate descriptor for these data. WHAT'S ALREADY KNOWN ABOUT THIS TOPIC? Last-observation-carried-forward (LOCF) imputation overestimates efficacy when adverse event withdrawals are high. Previous analyses of duloxetine in four chronic pain conditions reported mainly average pain changes using LOCF imputation. WHAT DOES THIS STUDY ADD? Responses were bimodal: patients generally experienced very good or very poor pain relief. Last-observation-carried-forward results were numerically lower (better) than true responder. Duloxetine was an effective analgesic in all four chronic pain conditions using highest level of evidence. BlackWell Publishing Ltd 2014-01 2013-06-03 /pmc/articles/PMC4302330/ /pubmed/23733529 http://dx.doi.org/10.1002/j.1532-2149.2013.00341.x Text en © 2013 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of European Pain Federation - EFIC ®. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Experimental & Clinical Pharmacology
Moore, RA
Cai, N
Skljarevski, V
Tölle, T R
Duloxetine use in chronic painful conditions – individual patient data responder analysis
title Duloxetine use in chronic painful conditions – individual patient data responder analysis
title_full Duloxetine use in chronic painful conditions – individual patient data responder analysis
title_fullStr Duloxetine use in chronic painful conditions – individual patient data responder analysis
title_full_unstemmed Duloxetine use in chronic painful conditions – individual patient data responder analysis
title_short Duloxetine use in chronic painful conditions – individual patient data responder analysis
title_sort duloxetine use in chronic painful conditions – individual patient data responder analysis
topic Experimental & Clinical Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302330/
https://www.ncbi.nlm.nih.gov/pubmed/23733529
http://dx.doi.org/10.1002/j.1532-2149.2013.00341.x
work_keys_str_mv AT moorera duloxetineuseinchronicpainfulconditionsindividualpatientdataresponderanalysis
AT cain duloxetineuseinchronicpainfulconditionsindividualpatientdataresponderanalysis
AT skljarevskiv duloxetineuseinchronicpainfulconditionsindividualpatientdataresponderanalysis
AT tolletr duloxetineuseinchronicpainfulconditionsindividualpatientdataresponderanalysis